In Phase C, contributors will acquire ABBV-744 and oral navitoclax. In Phase D, contributors will get ABBV-744 and ruxolitinib. Members will get treatment until illness progression or even the individuals are unable to tolerate the study drugs. and then endorse H3K27Ac at this location. Chromatin hyperacetylation could boost the accessibility https://ralphb322ozj5.activoblog.com/profile